Shay-Whey M Koh1, Dante Gloria, Joseph Molloy. 1. Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, 10 S. Pine Street, Baltimore, MD 21201, USA. skoh@umaryland.edu
Abstract
PURPOSE: To demonstrate corneal endothelial (CE) integrity enhanced during eye banking by a brief treatment of human donor corneoscleral explant (explant) with CE autocrine trophic factor vasoactive intestinal peptide (VIP). METHODS: Paired explants were used as control versus VIP (10 nM)-treated before storage in corneal storage medium (4°C). CE ciliary neurotrophic factor receptor (CNTFRα) and CNTF (0.83 nM) responsiveness in connexin 43 upregulation were monitored (Western blot analysis). CE damage in CNTF-modulated explants and corneal buttons from explants was quantified by analysis of panoramic and microscopic images of the alizarin red-stained corneal endothelium. CE cells scraped from the Descemet's membrane were counted. CE VIP receptor was demonstrated (Western blot analysis). RESULTS: CE cells in every VIP-treated, freshly dissected explant demonstrated higher CNTFRα levels than controls (100% vs. 142% ± 15%; P = 0.014; 7 pairs stored for 4 to 25 days). Nine days after VIP treatment of previously preserved explants, CNTF responsiveness was 174% ± 23% (P = 0.023; 4 pairs) of controls. Panoramic images of explants and corneal buttons revealed that VIP treatment reduced CE damage to 75% ± 6% (P = 0.023; 4 pairs) and 71% ± 11% (P = 0.016; 9 pairs) of controls, respectively, whereas CE damage to 39% (2 pairs) and 23% ± 4% (P < 0.001; 7 pairs), respectively, was revealed in microscopic images. Twenty-one days after VIP treatment of previously preserved explants, CE cell retention was 206% ± 38% (P = 0.008; 14 pairs) of the control. CE cells from human donor corneas expressed VIP receptor VPAC1 (not VPAC2). CONCLUSIONS: CE integrity during eye banking was enhanced by a brief treatment of the explant with the CE autocrine VIP.
PURPOSE: To demonstrate corneal endothelial (CE) integrity enhanced during eye banking by a brief treatment of humandonor corneoscleral explant (explant) with CE autocrine trophic factor vasoactive intestinal peptide (VIP). METHODS: Paired explants were used as control versus VIP (10 nM)-treated before storage in corneal storage medium (4°C). CE ciliary neurotrophic factor receptor (CNTFRα) and CNTF (0.83 nM) responsiveness in connexin 43 upregulation were monitored (Western blot analysis). CE damage in CNTF-modulated explants and corneal buttons from explants was quantified by analysis of panoramic and microscopic images of the alizarin red-stained corneal endothelium. CE cells scraped from the Descemet's membrane were counted. CE VIP receptor was demonstrated (Western blot analysis). RESULTS: CE cells in every VIP-treated, freshly dissected explant demonstrated higher CNTFRα levels than controls (100% vs. 142% ± 15%; P = 0.014; 7 pairs stored for 4 to 25 days). Nine days after VIP treatment of previously preserved explants, CNTF responsiveness was 174% ± 23% (P = 0.023; 4 pairs) of controls. Panoramic images of explants and corneal buttons revealed that VIP treatment reduced CE damage to 75% ± 6% (P = 0.023; 4 pairs) and 71% ± 11% (P = 0.016; 9 pairs) of controls, respectively, whereas CE damage to 39% (2 pairs) and 23% ± 4% (P < 0.001; 7 pairs), respectively, was revealed in microscopic images. Twenty-one days after VIP treatment of previously preserved explants, CE cell retention was 206% ± 38% (P = 0.008; 14 pairs) of the control. CE cells from humandonor corneas expressed VIP receptor VPAC1 (not VPAC2). CONCLUSIONS: CE integrity during eye banking was enhanced by a brief treatment of the explant with the CE autocrine VIP.
Authors: Hisham A Saad; Mark A Terry; Neda Shamie; Edwin S Chen; Daniel F Friend; Jeffrey D Holiman; Christopher Stoeger Journal: Cornea Date: 2008-08 Impact factor: 2.651
Authors: Rong Wen; Ying Song; Sten Kjellstrom; Atsuhiro Tanikawa; Yun Liu; Yiwen Li; Lian Zhao; Ronald A Bush; Alan M Laties; Paul A Sieving Journal: J Neurosci Date: 2006-12-27 Impact factor: 6.167
Authors: Wolfgang Jungraithmayr; Ingrid De Meester; Veerle Matheeussen; Ilhan Inci; Koen Augustyns; Simon Scharpé; Walter Weder; Stephan Korom Journal: Peptides Date: 2009-12-16 Impact factor: 3.750
Authors: Jonathan H Lass; Robin L Gal; Mariya Dontchev; Roy W Beck; Craig Kollman; Steven P Dunn; Ellen Heck; Edward J Holland; Mark J Mannis; Monty M Montoya; Robert L Schultze; R Doyle Stulting; Alan Sugar; Joel Sugar; Bradley Tennant; David D Verdier Journal: Ophthalmology Date: 2008-04 Impact factor: 12.079
Authors: Shay-Whey M Koh; Krish Chandrasekara; Cara J Abbondandolo; Timothy J Coll; Allan R Rutzen Journal: Invest Ophthalmol Vis Sci Date: 2008-04-25 Impact factor: 4.799
Authors: Shay-Whey M Koh; Yan Guo; Steve L Bernstein; James A Waschek; Xiuhuai Liu; Aviva J Symes Journal: Neurosci Lett Date: 2007-07-19 Impact factor: 3.046
Authors: Shubha V Y Raju; Meizi Zheng; Karl H Schuleri; Alexander C Phan; Djahida Bedja; Roberto M Saraiva; Omer Yiginer; Koenraad Vandegaer; Kathleen L Gabrielson; Christopher P O'donnell; Dan E Berkowitz; Lili A Barouch; Joshua M Hare Journal: Proc Natl Acad Sci U S A Date: 2006-03-06 Impact factor: 11.205
Authors: Zala Lužnik Marzidovšek; Tomas Blanco; Zhongmou Sun; Hamid Alemi; Gustavo Ortiz; Hayate Nakagawa; Sunil K Chauhan; Andrew W Taylor; Ula V Jurkunas; Jia Yin; Reza Dana Journal: Am J Pathol Date: 2021-11-11 Impact factor: 4.307
Authors: Yogesh Bhadange; Jeferson Lautert; Shimin Li; Edward Lawando; Edward T Kim; Mark C Soper; Francis W Price; Marianne O Price; Joseph A Bonanno Journal: Cornea Date: 2018-04 Impact factor: 2.651
Authors: Takefumi Yamaguchi; Aslihan Turhan; Deshea L Harris; Kai Hu; Harald Prüss; Ulrich von Andrian; Pedram Hamrah Journal: PLoS One Date: 2013-08-14 Impact factor: 3.240